Paul J. Galardy, M.D.

Closed for Enrollment

• A Pilot Study Of Rituximab (RTX) And Third Party Latent Membrane Protein (LMP)-Specific Cytotoxic T-Lymphocytes (LMP-TC) In Pediatric Solid Organ Recipients (SOT) With EBV-Positive CD20-Positive Post-Transplant Lymphoproliferative Disease (PTLD) Rochester, Minn.

  The purpose of this study is to assess how well rituximab and latent membrane protein (LMP)-specific T-cells work in treating pediatric solid organ recipients with Epstein-Barr virus-positive, cluster of differentiation (CD)20-positive post-transplant lymphoproliferative disorder. Monoclonal antibodies, such as rituximab may block tumor growth in different ways by targeting certain cells. LMP-specific T-cells are special immune system cells trained to recognize proteins found on post-transplant lymphoproliferative disorder tumor cells if they are infected with Epstein-Barr virus. Giving rituximab and LMP-specific T-cells may be better in treating pediatric organ recipients with post-transplant lymphoproliferative disorder than rituximab alone.

• Clinical And Epidemiological Studies In Pediatric Malignancies Rochester, Minn.

  The purpose of this study is to establish a bank of tissue, stool, and blood from pediatric participants newly diagnosed with a malignancy for future studies.